

Product datasheet for SR319500

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

BRCA2 Human siRNA Oligo Duplex (Locus ID 675)

Product data:

Product Type: siRNA Oligo Duplexes

Purity: HPLC purified

Quality Control: Tested by ESI-MS

Sequences: Available with shipment

Stability: One year from date of shipment when stored at -20°C.

of transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final

conc. 10 nM).

Note: Single siRNA duplex (10nmol) can be ordered.

RefSeq: <u>NM 000059</u>

UniProt ID: P51587

Synonyms: BRCC2; BROVCA2; FACD; FAD1; FANCD; FANCD1; GLM3; PNCA2; XRCC11

Components: BRCA2 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 675)

Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol

Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml

Summary: Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of

developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May

20201







Performance Guaranteed:

OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).